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estimate costs for in-and outpatients. RESULTS: Among the 264_PAND and
132_POST inpatients, 30% were 18 years old, and 45% were women. The mean
length of stay at general ward was of 6.5(6.1)-7.0(6.6) days (PAND and POST, respec-
tively); and between 8.2(5.0) and 11.5(15.2) days for ICU patients (7%_PAND and
20%_POST). Among employed (45.3% PAND and 37.7% POST) most went on sick
leave (99% and 93%) for about 31(37) and 38(27) days. Among outpatients
(215_PAND and 175_POST), about 25-35% were under 17 years old, and 50-57% were
women. The 94%(PAND) and 82%(POST) of employed (64,9% and 68,0%, respec-
tively) went on sick leave. Absenteeism length of was 11(12)-7(45) days. The mean
cost per inpatient was 6,028 € (SD6,251) in PAND and 6,939€(SD10,895) in POST.
For outpatients the mean cost was 749€ (SD886) in PAND and 421€ (SD686) in
POST. CONCLUSIONS: Contrary to what expected, resource utilization was quite
similar for both influenza waves. However, differences on mean cost were found
due to the slightly increase in inpatients health care utilization, and the decrease of
absenteeism among outpatients during the post-pandemic wave. These results
would be useful to assess the influenza real burden in Spain; both at individual and
population level.
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OBJECTIVES: To estimate direct medical costs of atopic dermatitis (AD) from a US
payer perspective. METHODS: Data came from a large employer-based longitudi-
nal claims database, which captures person-specific clinical utilization, expendi-
tures, and enrollment across inpatient, outpatient, prescription drug, and carve-
out services. A matched case-control study design was employed. Cases were
identified based on at least two AD-related medical claims with an International
Classification of Disease v9 codes of 691.8x or 692.x anytime during the calendar
year of 2009. Three controls were matched to each case based on age, gender, type
of health plan enrolled, and censes region. Multivariate robust regression models
were used to estimate the incremental burden of AD. A non-parametric bootstrap
technique with 1000 replications was used to estimate the distribution of the beta
coefficients and derive the 95% confidence limits. RESULTS:A total of 119,252 cases
were matched to 357,756 controls with an average age of 46 years (SD23.9), and
57% females. AD-related comorbidities such as allergic rhinitis, asthma, other
types of allergies, sleep disturbances and attention deficit disorders were signifi-
cantly greater (p0.01) in proportion among cases vs. controls. After adjusting for
all baseline differences, cases on an average had $912 (95% CL:$781-$1,042) greater
overall cost per subject compared to controls. Top three drivers were attributed to
outpatient costs (58%, $533), inpatient costs (22%, $201), and pharmacy costs (15%,
$139), respectively. Among cases, dermatology-related overall costs were 370%
(from $127 to $470) greater post index event. Over 80% of this increase was attrib-
utable to dermatology-related outpatient costs. Approximately, three additional
dermatology-related outpatient visits were observed in the follow-up period com-
pared to baseline. CONCLUSIONS: AD is costing the U.S. payer an additional $912
per-patient-per-year compared to subjects with no AD. Future research should
determine the impact of current treatment on the economic burden of this disease.
PHS19
MACRO-COSTING ANALYSIS OF HOSPITAL STAY IN HEART FAILURE PATIENTS
IN TURKISH SETTING
Ergene O1, Kocabas U1, Akyildiz I1, Eren NK1, Tan M2, Ozdemir O3
1Atatürk Training and Research Hospital, Izmir, Turkey, 2Servier Ilac ve Arastirma A.S.,
Istanbul, Turkey, 3Yorum Consulting Co. Ltd., Istanbul, Turkey
OBJECTIVES: The economic burden of heart failure (HF) has increased rapidly with
the increasing prevalence and incidence of HF patients all around the world. In this
abstract, the cost analysis of hospitalized HF patients is presented. METHODS: A
sample of hospitalizations (n166, year 2011) with diagnoses related with chronic
HF in a state hospital serving to a wide range of populations was evaluated. The
prices for ICU stay and cardiovascular procedures paid by Turkish state health
security system were applied. Indirect costs are not taken into account. RESULTS:
Twelve percent of the stays were in intensive care unit (ICU), 35% were in medical
ward only and 53% of the stays were partly in ICU and medical ward; average
duration were 2.513.09 days, 4.454.07 days and 6.955.08 days, respectively. ICU
stays are paid with fixed prices, without allowance for any extra payment for
services or procedures performed while the patient stays in ICU. Average daily and
total costs of ICU stay are calculated as 402€/day and 1006€, respectively. On the
other hand, procedures are paid per service, while the patient stays in medical
ward. Therefore the fixed amounts of payments for cardiovascular procedures,
which are mostly performed during the stay of HF patients, were averaged by the
frequencies of individual procedures. This yielded to 531€ per stay. Therefore the
total cost of stay was obtained as 1537€, and average daily cost of stay as 221€/day.
CONCLUSIONS: These figures are quite concordant with a previous analysis re-
ported in 2009 (total cost of stay 1617€ and daily cost of stay 245€/day) in which
micro-costing methods had been applied. Therefore these figures presented in this
report could be used local input parameters for health economics models for HF.
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OBJECTIVES: Inappropriate shocks are the most common complications of ICD,
causing a negative effect on patients’ morbidity and mortality. Little is known with
regards to the cost associated to the management of IS. The aim of the study was to
determine IS related factors and to evaluate its associated hospital cost.METHODS:
All patients implanted with an ICD where retrospectively analyzed through clinical
chart reviews in a Spanish hospital from 2003 to 2011. Demographic variables,
baseline cardiomyopathy, comorbidities, indication and type of ICD implanted
were registered. During the follow up period we identified the presence of IS, its
reasons and associated costs. RESULTS: A total of 227 patients were implanted
with an ICD, mean age 63.2 years (26-82). Eighty-six percent were men, 64.6% with
ischemic cardiomyopathy, 78.4% with heart failure, 70.4% with EF35% and 13.1%
with AF. The proportion of single, dual and three chambers ICD was 54.6%, 20.3%
and 25.1% respectively. After a median follow up of 4.46 years, 27 patients had had
42 IS episodes. Average time since implant to first IS was 1.3 years (range 0.02 to 3.84
years). Patients suffering from IS had higher mortality (33.3% vs 13.7%; p0.05).
Amost 67% of the episodes were due to supraventricular tachycardia, 12% to noise
detection, 19% to Wave T overdetection and 2.3% due to other causes. Sixty-three
percentages of the episodes generated an emergency visit and a 39% generated a
non-scheduled visit to the cardiologist. Seven episodes (16.7%) required hospital-
ization, six of whom required a surgical intervention. Average length of stay was
5.1 days. Finally, overall mean hospital cost appeared to be €5,175 per episode.
CONCLUSIONS: The cost of inappropriate shocks is driven by the reason of its
cause. The great majorities of the episodes were due to supraventricular arrhyth-
mias and finally resolved without the need for hospitalization.
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OBJECTIVES: To assess out-of-pocket expenses reported by patients receiving
chronic treatment for atrial fibrillation (AF) in five European countries. METHODS:
The EUPS-AF questionnaire was adapted from the 2008 Commonwealth Fund In-
ternational Health Policy Survey of Chronically Ill Adults. Computer-assisted digi-
tal telephone dialling was used to screen a random sample from the entire adult
populations of France, Germany, Italy, Spain and the UK. Structured telephone
interviews were conducted between February and July 2011. RESULTS: Interviews
were conducted with 1507 patients (France, n300; Germany, n300; Italy, n302;
Spain, n305; UK, n300). On average, 40% of patients had incurred no out-of-
pocket expenses for medical treatment or services over the past 12 months (range,
18% [Italy] to 75% [UK]). Of the 582 patients who reported out-of-pocket expenses
(mean, €705), 221 (44%) declared that the costs included those due to AF (mean,
€466). The lowest mean out-of-pocket cost per patient for AF care was reported in
France (€92 [median, €82], n14) and the highest in the UK (€1573 [median, €114],
n29). The majority of out-of-pocket expenses for AF were non-medical costs for
treatment and services not covered by insurance, including travel and household
help. The proportion of patients who claimed cost as a reason for not filling a
prescription or skipping doses ranged from 3% in the UK and Spain to 10% in
France. Failure to receive treatment due to lack of reimbursement was experienced
least frequently in the UK (1% of patients) and most frequently in Germany (28% of
patients). CONCLUSIONS: The EUPS-AF highlights differences in out-of-pocket ex-
penses and levels of treatment reimbursement that patients with AF have to pay in
five European countries. Payers, health care policy makers and clinicians should all
be aware that the financial burden of AF is linked to treatment adherence and may
affect patient satisfaction and treatment outcome.
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OBJECTIVES: Streptococcus pneumoniae causes a wide spectrum of illness from
upper respiratory tract infection to severe invasive pneumococcal disease (IPD),
defined as the identification of S. pneumoniaea normally sterile site. The most
severe IPD forms are meningitis, bacteraemia and septicaemia. Older adults are in
an increased risk of death from IPD. The former socialistic countries of the central
Europe form a unique region with specific health care and epidemiology charac-
teristics, and where the local evidence on the underlying epidemiology is scarce.
The objective was to estimate the economic burden of IPD in those50 years of age
in the Czech Republic (CR), Slovakia (SK), Poland (PL), and Hungary (HU) using most
recent data available. METHODS: The incidence of IPD stratified by age groups
50-64, 65-74, 75-84 and 85 was obtained from national surveillance systems (PL,
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CR, SK) and insurance records (HU). Direct costs from the payer’s perspective were
based on published national sources (CR, SK), DRG lists (PL) and the insurance
records (HU). RESULTS: The incidence of hospitalized bacteraemia/sepsis and
meningitis per 100,000 person years were: 2.07 and 1.34 (CR), 1.2 and 0.49 (SK), 0.66
and 0.32 (PL), and 3.16 and 1.01 (HU). The case fatality rate was: 31% and 25%, 12%
and 25%, 40% and 63%, and 11% and 29%. An exponential increase in both measures
was apparent with advancing age. The total economic burden of IPD in adults over
50 was: EUR 666,050; 159,528; 180,015 and 140,249. Adults 65, who represent 41%
of the combined population, account for 54% of the costs. CONCLUSIONS: The IPD
burden in adults increases with age, and is associated with a high risk of death.
Higher incidence in HU obtained from insurance records seems to more reliably
reflect the reality and highlights systematic underreporting of national surveil-
lance systems.
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OBJECTIVES: To estimate the stroke related disease burden in terms of health care
resource utilization and average per-patient costs among patients with a prior
diagnosis of non-valvular atrial fibrillation (NVAF) in India. METHODS: Data were
collected retrospectively in three large multidisciplinary community hospitals in
three cities in India. Medical charts of 400 patients diagnosed with stroke and NVAF
from June 1, 2011 to September 1, 2011 were reviewed. Data abstracted were demo-
graphic characteristics, clinical diagnosis, risk factors, comorbid conditions, date of
diagnosis/admission, date of discharge, and types of inpatient procedures. Data
regarding outpatient services such as physician visits, laboratory tests, INR moni-
toring, diagnostic tests, nursing services, and speech/physiotherapy over a three
month period post-discharge were obtained via patient follow-up surveys. Costs
associated with inpatient services were obtained from hospital discharge bills and
the pricing menu of the three hospitals. RESULTS: The mean age of patients in the
study was 59 (SD 10) and the majority of patients (62%) were male. Of the 400
patients, 61% had ischemic stroke and about 60% of the patients were moderate to
moderate-severe disabled based on the modified Rankin Scale. The mean length of
stay for patients with ischemic stroke was 16 days (SD 4). The direct medical costs
for patients with moderate or more severe ischemic stroke (inpatient and outpa-
tient) over the 3 month follow-up period was Indian rupees, Rs 130,976 (SD 3,913)
with inpatient hospital costs accounting for a major portion (Rs 114,202) of the
overall costs (per patient). CONCLUSIONS: The findings of the study indicated that
the acute treatment for 3 months post ischemic stroke among NVAF patients im-
poses considerable economic burden (US $7,138) among patients in India. As inpa-
tient costs are major cost drivers, clinical efforts should focus on timely manage-
ment of NVAF induced strokes and use of preventive treatments.
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OBJECTIVES:To calculate the health care cost of traffic accidents occurring in night
or daylight under low visibility. METHODS: Data on traffic accidents derive from
the database of Hungarian Central Statistical Office (HCSO). We assessed the cost of
both health services in kind and health services in cash. The direct cost related to
traffic accidents were derived from the financial database of the National Health
Insurance Fund Administration, the only health care financing agency in Hungary
(Hungarian DRG point system version 5.0). Cost of benefits in cash was calculated
with an average sick pay. The average recovery period of patients with traffic
accidents was assumed 4 months. RESULTS: A total of 20635 persons were injured
and 1106 persons were died on the road by traffic accident. 45 percent of casualty
has been taken in night or daylight under low visibility. Average cost of restricted
visibility accidents is 510886 HUF per capita (approx. 2041 EURO). We calculated an
average sick pay 119365 HUF (approx. 477 Euro) per capita per month. The expen-
ditures of the National Health Insurance Fund Administration could easily reach
the 17 billion HUF (approx. 67.9 million Euro) per years. CONCLUSIONS: Traffic
accidents and subsequent medical conditions are important burden for the Hun-
garian health insurance system with an annual expenditure of 17 billion HUF (97,9
million EURO). Better illumination, law regulation, appropriate education and traf-
fic instructions might decrease the costs related to accidents on the road.
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OBJECTIVES: Gastrointestinal bleeding is one of the most common causes of med-
ical attention in-hospital demand, with high impact on morbidity, mortality and
costs of care. The aim of this study was to evaluate from the public payer perspec-
tive in Mexico, the cost of care of patients with gastrointestinal bleeding.
METHODS: Through review of medical records of patients with gastrointestinal
bleeding from January to March 2012 in a hospital in the Mexican Social Security
Institute (IMSS) we evaluated the length of hospital stay, laboratory tests, endos-
copy and pharmacological treatment prescribed. We used as reference the 2011
database of the institution and expressed the cost in U.S. dollars (USD) at an ex-
change rate of 13.72 Mexican pesos/USD [June 2012] and calculated the average cost
per patient, we identified the component of major cost and identify the factor
associated with higher cost. RESULTS:We included 70 patients with mean age 68
14 years, 61% were women. 80% of cases had a comorbidity, the most frequent was
systemic arterial hypertension (90%). On average hospital stay was 8 4 days. The
average cost per patient was 3.776 USD (1.490 USD- 8.180). The major cost compo-
nent was hospital stay accounting for 81% of total costs. In patients Age over 85
years, the presence of comorbidities or gender were no associated with higher cost
(p 0.05). CONCLUSIONS: Gastrointestinal bleeding is a major cause of resource
utilization for the IMSS, the main component are the days of hospital stay which
cause a high economic impact on accessibility to other hospital claims.
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OBJECTIVES: In France, 4-10% of the population is annually affected by influenza.
This represents direct and indirect costs, which vary according to the dominant
influenza virus strain circulating. Policy makers are interested in its burden, for
better allocating resources for prevention and control measures. As international
literature regarding seasonal influenza B is rare and not entirely applicable in
France, our study aims to assess its costs in 2010/2011 under the French Health
Insurance perspective. METHODS: Cases: patients of all ages, consulting for an
acute respiratory infection a physician, member of an influenza surveillance net-
work in France (GROG network), completing the routine clinical form and whose
nasopharyngeal swab was lab confirmed positive for influenza B. Physicians com-
pleted follow-up questionnaires 7 and 28 days after swabbing. Costs (consults,
drugs, exams, hospitalization and daily allowances) were assessed for each pa-
tient. Treatments costs were modelled using linear, tobit and probit regressions
(variables: costs, risk factor, vaccination, age group). Total costs estimation for the
French Health Insurance were calculated by multiplying total costs per patient, flu
attack rate and population. RESULTS: N201 patients were included. Influenza B
mean cost was 90.63€ (SD 132.76) per patient. Risk factors or influenza vaccine
status did not impact the mean cost. In children and older people these costs were
very similar (0-4 yo76.74€, 5-14 yo75.45€, 65 yo72.50€). Main cost items were
follow-up consults and antibiotics. For adults, costs almost doubled, reaching ap-
proximately 141.25€ per patient, due to work absenteeism. Total influenza B costs
for the National Health Insurance were estimated on almost 400 million Euros in
France during 2010/11. CONCLUSIONS: The results show that in a season where
influenza B is dominant, it causes an important economic impact. Further investi-
gations of strategies (vaccines) for reducing influenza B cases, providing evidence
for policy-makers’ decisions are in progress.
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OBJECTIVES: To assess the clinical and demographic characteristics, utilization,
and cost patterns of human immunodeficiency virus (HIV) patients in the U.S.
veteran population. METHODS: A retrospective analysis was performed using the
Veterans Health Administration (VHA) Medical SAS Datasets from October 1, 2007
to September 30, 2011. All U.S. veteran beneficiaries diagnosed with HIV were iden-
tified using International Classification of Disease 9th Revision Clinical Modifica-
tion (ICD-9-CM) diagnosis codes 042.xx and V08.xx. Descriptive statistics were cal-
culated as means  standard deviation (SD) and percentages to measure
demographic, cost, and utilization distribution in the sample. RESULTS: A total of
2,432 patients were diagnosed with HIV, who were most frequently designated as
Caucasian (n1,201, 49.38%) and often lived in the southern parts of the United
States (n905, 37.21%). Common comorbidities included hypertension (n1,531,
55.55%) and diabetes (n558, 22.94%). Survival rates were high for all age groups
(age 39: 98.21%; 40-64 years: 93.48%; 65: 87.11%). Outpatient services were uti-
lized by 99.92% of HIV patients, followed by inpatient (20.44%) and outpatient emer-
gency room (ER) visits (7.11%). An average number of 0.39 inpatient visits and 21.01
outpatient visits per patient occurred during the 1-year follow-up period. Outpa-
tient office ($10,558, SD$12,856), outpatient ER ($36, SD$240), and inpatient
($8,371, SD$35,444) values contributed to follow-up health care expenditures.
CONCLUSIONS: U.S. veterans with HIV experienced a high average number of
outpatient visits during the follow-up period as well as frequent comorbidities and
high survival rates. These may have translated to the high outpatient expenses
evident in the study.
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OBJECTIVES:The management of atrial fibrillation (AF) represents a significant and
increasing burden on the UK National Health Service (NHS). Understanding this
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